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Abstract
Background: Human Papillomavirus (HPV) E6 induced p53 degradation is thought to be an essential activity by which high-
risk human Alphapapillomaviruses (alpha-HPVs) contribute to cervical cancer development. However, most of our
understanding is derived from the comparison of HPV16 and HPV11. These two viruses are relatively distinct viruses, making
the extrapolation of these results difficult. In the present study, we expand the tested strains (types) to include members of
all known HPV species groups within the Alphapapillomavirus genus.
Principal Findings: We report the biochemical activity of E6 proteins from 27 HPV types representing all alpha-HPV species
groups to degrade p53 in human cells. Expression of E6 from all HPV types epidemiologically classified as group 1
carcinogens significantly reduced p53 levels. However, several types not associated with cancer (e.g., HPV53, HPV70 and
HPV71) were equally active in degrading p53. HPV types within species groups alpha 5, 6, 7, 9 and 11 share a most recent
common ancestor (MRCA) and all contain E6 ORFs that degrade p53. A unique exception, HPV71 E6 ORF that degraded p53
was outside this clade and is one of the most prevalent HPV types infecting the cervix in a population-based study of 10,000
women. Alignment of E6 ORFs identified an amino acid site that was highly correlated with the biochemical ability to
degrade p53. Alteration of this amino acid in HPV71 E6 abrogated its ability to degrade p53, while alteration of this site in
HPV71-related HPV90 and HPV106 E6s enhanced their capacity to degrade p53.
Conclusions: These data suggest that the alpha-HPV E6 proteins’ ability to degrade p53 is an evolved phenotype inherited
from a most recent common ancestor of the high-risk species that does not always segregate with carcinogenicity. In
addition, we identified an amino-acid residue strongly correlated with viral p53 degrading potential.
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Introduction
The Papillomaviridae have a circular genome of about 7900 bp.
The genome typically contains seven or eight open reading frames
(ORFs). The early genes E1 and E2 are involved in viral genome
replication, while E6 and E7 have been shown to be oncogenes.
The late genes L1 and L2 encode structural proteins that comprise
the viral capsid. Nucleotide similarity across the L1 ORF has been
used as a guide for viral classification [1,2]. Members of the same
genus, named according to the Greek alphabet, share more than
60% nucleotide sequence identity across the L1. Members of these
genera are clustered into species comprised of distinct PV strains
(commonly referred to as ‘types’) that are .10% different from
any other previously defined type.
Compelling data implicate HPV as the long sought sexually
transmitted agent of cervix cancer [3], the second most common
cancer among women worldwide [4]. Indeed, alpha-HPVs have
been detected in more than 90% of cervical cancer tissues [5]. The
ability of high-risk alpha-HPV infections to progress to malignancy
is due, in large part, to the expression of the E6 and E7 oncogenes
(reviewed in [6,7,8]). The E6 proteins are about 150 amino acids
long and contain 2 zinc finger domains. One of the first functions
associating a mechanism of carcinogenicity of the HPV16 and
HPV18E6 proteinswas their biochemicalability todegrade cellular
p53 protein and inhibit p53 growth suppressor functions [9]. The
p53 gene has pleiotropic activities and is inactivated in a majority of
cancers (reviewed in [10,11,12]). Normally, p53 is activated in
response to DNA-damaged stress signals and results in cell cycle
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indicated that E6s from high-risk HPV types HPV16 and HPV18
significantly decreased the half-life of p53, while low-risk type
HPV11 did not [13,14]. Based on these observations, the ability to
degrade p53 was assumed to be uniquely associated with, and a
major cause of the oncogenicity by high-risk HPVs.
One important caveat in this generalization is the observation
that HPV6 and HPV11 are proportionally more commonly found
in condyloma accuminata and laryngeal papillomas. Whereas,
HPV16 and HPV18 primarily infect the cervix, indicating a
preferential tissue tropism difference between members of
divergent alpha-HPV species groups [1,2]. Given that differences
in tissue tropism between the prototypical high- and low-risk types
might account for the differences in E6 functionality based on
ancient evolutionary niche adaptation and sequence divergence,
we sought to determine the evolutionary origin of E6 mediated
p53 degradation. We designed an in vivo screening assay to analyze
representative HPV types from each of the 13 alpha-HPV species
for p53 degradation. The data were then analyzed in the context
of both the phylogenetic grouping and the oncogenic potential of
the HPV types considered. Based on these data, we argue that the
E6 ORF capability to degrade p53 was inherited from a most
recent common ancestor (MRCA) of the alpha 5, 6, 7, 9 and 11
species groups. Nevertheless, this phenotype was subsequently
acquired in a different lineage, not associated with cancer. This
implies that p53 degradation by E6 is not sufficient to designate a
virus as oncogenic. In addition, the evolved phenotype arising
independently in two different lineages suggests that the p53
degradation phenotype might share amino-acid residues and/or
domains not shared by the non-degraders. Through the use of
sequence alignments and site-directed mutagenesis we identified a
single amino acid position highly correlated with the potential to
degrade p53. We show that context of changes in this amino acid
is important in phenotype switching. These studies indicate that
nonsynonymous changes in different lineages can have profound
phenotypic affects.
Materials and Methods
Plasmid expression vectors
Templates for the E6 ORFs were either cloned from previously
typed clinicalspecimens (HPV types 2,10, 11, 16, 18, 30, 52, 53, 56,
62, 66, 70, 71, 73, 90 and 106) or obtained from cloned HPV
genomes generously provided by E.-M. DeVilliers and H. zur
Hausen (Deutsches Krebsforschungszentrum, Heidelberg, Ger-
many; HPV types 6, 40); R. Ostrow (University of Minnesota,
Minneapolis; HPV type 26); A. Lorincz (Digene Diagnostics, Silver
Spring, MD; HPV types 31, 35); G. Orth (Institut Pasteur, Paris;
HPV types 34, 39, 42, 54) and T. Matzukura (National Institute of
Health,Tokyo;HPVtypes58,61). The E6ORFs were amplifiedby
PCR using a 59 primer that included an HA-tag sequence in frame
with the E6 ORF and engineered restriction enzyme digestion sites,
as described below. HPV16 HA-E6 was cloned into the NotI-EcoRI
sites, whereas all other HA-E6swerecloned into the AgeI-EcoRI sites
of the pQCXIN vector (BD Biosciences Clontech, San Jose, CA).
The presence and orientation of the E6 ORFs were confirmed by
sequencing. The reference variant of each type was chosen, except
for HPV16 where an African-1 lineage E6 was cloned from a
clinical sample (AF472508) [15]. Since we did not detect the
HPV71 reference sequence in any of our molecular epidemiology
studies, a clinical HPV71 isolate was used (AY330623). The p53
ORF was PCR amplified from a plasmid kindly provided by Dr.
Liang Zhu (Albert Einstein College of Medicine) incorporating an
HA-tag at the amino-terminus as described [16] and cloned into the
HindIII-EcoRI sites of the pCR3 vector (Invitrogen Corporation,
Carlsbad, CA).
Cell lines and transfection
The 293T and C-33A cell lines were the generous gift of Dr.
Liang Zhu. The C-33A cell line is an HPV negative cervical
cancer cell line expressing a mutant p53 protein [17,18] and 293T
is a human embryonic kidney cell line with a high transfection
efficiency that facilitates the study of ectopically expressed genes.
The 293T cell line has high levels of endogenous p53 due to the
expression of simian virus 40 (SV40) large T antigen, which
stabilizes and inactivates the p53 protein. Both cell lines were
maintained in Dulbecco’s modified Eagle’s medium (DMEM) with
10% fetal bovine serum (FBS). The 293T cell line was transfected
using a calcium phosphate method [19]. The C-33A cell line was
transfected using Lipofectamine Plus (Invitrogen Corporation,
Carlsbad, CA) according to the manufacturer’s recommendations.
For the double immuno-fluorescence experiments, C-33A cells
were transfected using the ExGen reagent (Eurogentec, Belgium).
Western blot analysis
The proteasome inhibitor, MG132 (Calbiochem, San Diego,
CA), was dissolved in DMSO (Sigma-Aldrich, Inc. St. Louis, MO)
at a concentration of 10 mM. Twenty-four hrs after transfection,
the cells were either treated with MG132 (10 uM final
concentration) or DMSO for 16 hrs and the cells were then lysed
in 300 ul RIPA buffer (Santa Cruz Biotechnology, Inc. Santa
Cruz, CA) in a 60 mm plate. The protein concentration of cell
lysates was measured using the Bio-Rad Protein Assay (Bio-Rad,
Hercules, CA) according to the manufacturer’s recommendations.
Equal amounts of protein lysates for each cell line (40 ug for 293T
and 20 ug for C-33A) were separated by SDS-PAGE and analyzed
by Western blot as previously described [20]. The qualitative
ability of each E6 to degrade p53 expression levels was scored by 2
investigators based on 3 independent experiments. The ability of
the E6 protein from different types to degrade p53 was concordant
in all experiments.
Determination of p53 half-life co-transfected with HPV E6
293T cells were transfected with HA-p53 and E6 plasmids as
described above. Cycloheximide (CHX, Sigma-Aldrich, Inc.), an
inhibitor of protein synthesis in eukaryotic organisms, was added
to the medium 36 hrs after transfection at 50 ug/ml final
concentration. The cell lysates were collected at 0, 30, 60 and
120 mins after addition of CHX. Western blot analysis was
performed as describe above. The Western blot results were
scanned and the intensity of the HA-p53 and b-tubulin bands were
quantified by ImageQuant v. 5.0. The half-life (t1/2) was
extrapolated from the data corresponding to the time needed to
decrease one unit of log2 (band intensity at time zero).
Site-directed mutagenesis
Site-directed mutagenesis was performed using the GeneTailor
Site-Directed Mutagenesis System (Invitrogen Corporation) ac-
cording to the manufacturer’s recommendations. All mutations
were confirmed by sequencing the complete E6 ORF using
flanking primers in the vector.
Double immuno-fluorescence assay
The double immuno-fluorescence experiments were performed
as described previously ([21]). Briefly, C-33A cells grown on
coverslips were transfected with the indicated E6 plasmids.
Twenty-four hrs later, cells were rinsed with PBS, fixed in 4%
HPV E6 Degradation of p53
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5 min in 0.1% Triton X-100. Coverslips were incubated for
30 min in blocking buffer (DMEM, 10% FCS) and treated as
described below. For simultaneous observation of the native p53
and HA-E6, cells were first incubated with polyclonal anti-p53
antibody (FL393, Santa Cruz Biotechnology) diluted 1/200 in
blocking buffer, washed with PBS and then incubated with mouse
monoclonal anti-HA-tag antibody diluted 1/3000; thereafter, cells
were incubated with a goat anti-rabbit IgG antibody conjugated to
Alexa Fluor 568 (Molecular Probes) diluted 1/2000, washed with
PBS, incubated with goat anti-mouse IgG antibody conjugated to
Alexa Fluor 488 (Molecular Probes) diluted 1/2000, washed with
PBS, and stained for DNA with DAPI. Coverslips were mounted
onto slides and visualized with a Zeiss fluorescence microscope.
Results
Establishment of an in vivo p53 degradation assay
p53 degradation is believed to play an important role in the
oncogenic effects of E6 proteins from high-risk genital HPVs. In
order to evaluate the E6 activity from a large number of HPV
types, we designed a high-throughput in vivo p53 degradation
assay. In this assay, the levels of ectopically expressed p53 in
mammalian cells in the absence or presence of co-expressed E6
protein are evaluated by Western blotting. To validate the assay,
we used three E6 proteins encoded by types with known activity
for p53 degradation [9,13] (Figure 1A). HPV11 E6 does not
degrade p53 [13], whereas the E6 proteins from HPV16 and
HPV18 have been shown to degrade p53 [22]. The three E6
ORFs were HA-tagged and co-expressed with HA-tagged p53 in
C-33A cells. Compared to the empty vector control (pQCXIN),
HPV11 E6 did not reduce the level of HA-p53, whereas HPV16
and HPV18 E6 reduced HA-p53 levels. Proteasomal inhibition
with MG132 significantly increased the HA-p53 levels in cells
expressing HPV16 and HPV18 E6, as compared to cells
transfected with control vector or HPV11 E6 (figure 1A).
In order to show that the p53 degradation by HPV E6 in this
assay was a post-translational event, we used the protein synthesis
inhibitor cycloheximide (CHX) to estimate the half-life of p53 in
the presence or absence of co-expressed E6. 293T cells were co-
Figure 1. HPV E6-mediated p53 degradation. A) HA-tagged p53 levels were visualized by Western blot after co-transfection with HA-tagged
HPV E6 from HPV11, HPV16 and HPV18 into C-33A cells. Lanes 1, 3, 5 and 7 show results from co-transfection of HA-p53 and vectors indicated at the
top of the figure. Lanes 2, 4, 6 and 8 show the p53 levels after treatment with MG132, as indicated at the top of the figure. b-tubulin was visualized as
a loading control. (B) Half life of HA-p53 in transfected 293T cells. 293T cells were transfected with HA-p53 and control (pQCXIN) or E6 ORFs (HPV11,
HPV18, HPV53, HPV56 and HPV66). The band intensities were determined from the scanned Western blot using ImageQuant and the signals at time 0
were defined as 100%. The band intensities of the indicated time points were normalized to time 0.
doi:10.1371/journal.pone.0012816.g001
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HPV53, HPV56 or HPV61. The results showed that p53 half-life
was decreased from greater than 2 hours (empty vector, HPV11,
HPV61) to approximately 30 minutes (HPV18, HPV53, HPV56)
(Figure 1B). Thus, E6 from HPV18, HPV53 and HPV56
decreased the levels of p53 via a post-translational effect, whereas
E6 from HPV types 11 and 61 did not.
E6-associated reduction in p53 levels is associated with
phylogenetic grouping
To evaluate the phylogenetic distribution of E6 activity to
degrade p53, we tested E6 ORFs from representative types from
each HPV alpha species group (Figure 2). Expression of the E6
protein from HPV types in species groups a9, a11, a7, a5 and a6
resulted in degradation of p53, whereas E6 from species a10, a8,
a1, a13, a2, a4, a15 and a3 did not. An important exception was
the observation that the E6 protein from HPV71 (a15) also
reduced p53 levels.
These data demonstrated that the ability to decrease p53 levels
was highly correlated with phylogenetic grouping and evolutionary
descent. All the types that decreased p53 levels, except HPV71,
share a most recent common ancestor (MRCA) (Figure 2).
Nevertheless, it was noted that not all the E6 proteins that
down-regulated p53 were from HPV types classified as group 1
carcinogens (i.e., sufficient evidence to be classified as carcinogenic
to humans) by the Working Group of the WHO International
Agency for Research on Cancer (IARC) [23,24]. For example,
HPV53 and HPV70 decreased p53 expression even though they
are not epidemiologically associated with cervical cancer [5].
Identification of a single amino acid associated with the
E6’s ability to degrade p53
Analyzing the p53 degradation potential in the context of
phylogenetic relationships revealed that p53 degradation is highly
correlated with the tree topology. This indicates an ancient lineage
specific evolved trait in the MRCA of the alpha 5, 6, 7, 9 and 11
species groups and a more recent event in HPV71 (figure 2).
Consistent with this notion, it should be possible to differentiate
p53 degraders from non-degraders by the presence/absence of key
amino acid residues and/or motifs. Based on an alignment of HPV
types tested in this study (Figure 3), we identified a position
(position 31, bold in the figure) at which the HPV types not able to
decrease p53 (except HPV40) have a basic residue (lysine, K or
arginine, R). In contrast, none of the E6 ORFs that degrade p53
have a basic amino acid at this site (p,0.01, x
2). This site is 2
amino acids upstream of a proposed E6-AP binding region
(shaded in Figure 3) [25,26]. HPV71, the only p53 degrader that
did not cluster with the HR-HPVs, has an asparagine residue (N)
at this site. Interestingly, HPV90 and HPV106, HPV71’s closest
relatives, have a ‘typical non-degrader’ lysine residue (K) at this
site. This suggested a potential role for this amino acid in the
degradation of p53 by E6.
The significance of this basic aa was investigated by identifying
its structural location on the E6 protein. Although the complete
structure of the E6 protein is currently unknown, the structure of
the C-terminal domain of HPV16 E6 (E6C) has been determined
[21]. Based on sequence similarities, it has been suggested that the
fold of E6N domains should be comparable to that of E6C
domains, and should be relatively conserved amongst different
HPV types. Examination of the identified position (corresponding
to HPV16 T17) in structure-based alignments of E6C and E6N
domains [21] revealed that this residue aligns with a solvent-
exposed position of the E6C domain situated at the N-terminus of
the first helix of the domain [21]. Therefore, this residue may be
involved in a protein-protein interaction interface in the E6/
E6AP/p53 complex responsible for p53 degradation. Moreover,
its exposed character makes it a suitable candidate for site-directed
mutagenesis without expected changes to the structural integrity of
the protein.
To investigate the effects of ‘‘position 31’’, we constructed
single-point mutant E6 proteins: HPV71 E6 N24K, HPV90 E6
K16N and HPV106 E6 K31N. All E6 mutants were tested for
their ability to degrade p53 using the Western blot assay. In
parallel, the constructs were also tested for their ability to decrease
p53 levels in a previously described single cell assay [21]. These
mutations changed the activity of HPV71, HPV90 and HPV106
E6s (Figure 4A). The HPV71 N24K mutant completely abolished
the p53 degradation ability of wt HPV71 E6. Whereas, wild type
HPV90 E6 induced a slight MG132-sensitive decrease in p53
levels and a slight, but detectable decrease of p53 signal in single
transfected cells (Figure 4B); the K16N mutation of HPV90 E6
enabled it to fully degrade p53 in Western blot-based assays
(Figure 4A) and to turn off p53 signal in single transfected cell
assays (Figure 4B) as efficiently as HPV16 E6. Wild type HPV106
did not decrease the p53 levels in either assay. The HPV106 E6 K-
N mutant had weak activity for p53 degradation as assayed by
immunoblot (Figure 4A), and did not induce p53 degradation in
single transfected cells (figure 4B). Taken together, these data
indicate a contribution of this position to p53 degradation.
Discussion
Among the human Alphapapillomaviruses, a subset is considered
oncogenic. The two major HR-types, HPV16 and HPV18 are
responsible for about 70% of all cervical cancer cases [5,27].
Recent work based on epidemiological and phylogenetic studies
showed that all HR viruses cluster together in a HR-clade arguing
that a common ancestor acquired an oncogenic potential (Fig 2)
[28]. However, the most recent report by the working group of the
IARC found that only a limited number of HPV types within this
HR-clade had sufficient evidence to conclude that they were
cervix cancer carcinogens [23,24]. Nevertheless, there is compel-
ling evidence supporting an evolutionary aspect to HPV induced
carcinogenesis. In this study, we set out to investigate a well-
characterized phenotype associated with the molecular basis of
HPV oncogenicity from a phylogenetic perspective.
E6-mediated p53 degradation has been considered a hallmark
function of oncogenic HPVs, although E6 is a highly multi-
functional protein [7,8]. The attribution of cancer risk being
associated with proteasomal degradation of p53 has been mainly
based on studies comparing low risk types HPV6/11 to high-risk
types HPV16/18. These viruses, although all members of the
Alphapapillomavirus genus have different tissue tropisms, cause
different histological lesions (e.g., flat vs. verrucous) and are
phylogenetically distant. These observations indicate that when
extrapolating factors associated with cancer risk, evolution and
biological niche adaptation (e.g., tissue tropism) need to be
considered. In order to address the evolutionary importance of
p53 degradation in the oncogenic process, we analyzed the ability
of E6s from 27 HPV types (representing all alpha-HPV species) to
degrade p53 in vivo. Our results demonstrate that although all
high-risk types did in fact degrade p53, several low-risk types not
epidemiologically associated with cervix cancer (e.g., HPV53,
HPV70 and HPV71) also decreased p53 levels. A recent in vitro
study [29] independently confirmed that E6 of HPV53, HPV56,
HPV66 and HPV70 degraded p53 as efficiently as E6 of the
highest-risk alpha-PV types. Interestingly, data from cutaneous
HPV E6 Degradation of p53
PLoS ONE | www.plosone.org 4 September 2010 | Volume 5 | Issue 9 | e12816Figure 2. Phylogeny of alpha-HPVs and degradation of p53 by HPV E6 ORFs. HPV E6 activity on HA-p53 steady state levels were
determined by Western blot using the assay shown in Figure 1A. The phylogenetic tree at the left was constructed using the combined early gene
sequences as previously reported [35]. Epidemiological carcinogenicity was extrapolated from recent reviews [23,24] and is indicated in the column
labeled ‘‘carcinogenic risk’’: ++, highly oncogenic; +, oncogenic; +/2, probably oncogenic; 2, not significantly associated with cervix cancer; NA,
insufficient data. The p53 levels after co-transfection with E6 from each type indicated on the left are shown in the far right column labeled, ‘‘p53’’
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development of non-melanoma skin cancer (NMSC) in the rare
hereditary disease epidermodysplasia verruciformis (EV)
[30,31,32] indicated that these viruses neither bind to, nor
degrade p53. Therefore, the phylogenetic position of the virus is
a more relevant criterion than its oncogenic risk for predicting
ability to degrade p53. Based on these observations, we
hypothesize that p53 degradation was adapted by the most recent
common ancestor (MRCA) of the current HR-HPV clade in order
to successfully adapt to a biological niche within the genital
mucosa. All extant members of the HR-clade have inherited this
p53 degradation phenotype irrespective of oncogenic potential.
Embedded within this hypothesis is the notion that p53
degradation might be necessary, but is not sufficient for HPV
induced oncogenesis. Thus, p53 degradation appears to be
important for these viruses to complete their life cycle in this
particular niche of the human body.
Furthermore, these results suggest that there are additional
biochemical activities distinguishing closely related non-oncogen-
ic (e.g., HPV53 and HPV70) from oncogenic members of the
high-risk clade consistent with the plethora of activities associated
with E6 [8]. However, since E6 and E7 expression is needed for
successful transformation of primary keratinocytes [33], it is
possible that the differentiating functionality lies within the E7
protein and/or an interaction of functions between the E6 and
E7 proteins, introducing additional complexity into the biological
system. Identifying specific changes associated with epidemiolog-
ical cancer risk should lead to a better understanding of the
oncogenic mechanisms utilized by high-risk HPVs that distin-
guish them from their phylogenetically closely related nearest
neighbors.
Of note, HPV71 was one of the three most prevalent HPV types
detected in a population based study in Costa Rica [34]. In
addition, HPV71 is one of the types most likely to cause persistant
cervicovaginal infection, but is not associated with neoplastic
changes [28]. It is feasible that E6 activity to degrade p53 provides
HPV71 an evolutionary advantage accounting for in part, its high
population prevalence and persistence.
In an attempt to understand the evolutionary adaptations that
occurred in the MRCA of the HR-clade, we identified a single
amino acid site (‘‘position 31’’) correlated with the ability to
degrade p53. This position, situated within the putative helix 1 of
the E6N domain, is predicted to be fully exposed to solvent and
therefore ideally positioned for participating in protein-protein
interactions possibly important for p53 degradation. Both
sequence analysis and mutagenesis data suggest that at this
position a polar (e.g., T or N) or negatively charged residue
supports p53 degradation activity, whereas a positively charged
residue (R or K) is generally unfavorable to p53 degradation
activity. This position may be part of an interacting surface
domain important for the p53 degradation process. However, this
interacting surface probably comprises several other amino-acid
chains. Depending on the HPV type, the importance of position
31 may vary.
(with and without MG132) and the results are summarized in the column labeled‘‘Qp53’’. Endogenous b-tubulin (far right column) represents a
loading control. The alpha-HPV species groups are indicated by brackets with a number to the right. The empty vector control, pQCXIN is shown at
the bottom.
doi:10.1371/journal.pone.0012816.g002
Figure 3. Alignment of HPV alpha E6 ORFs. The alignment of all 27 E6 ORFs tested in Figure 2 is shown. HPV types degrading p53 are shown at
the top of the alignment and those not degrading p53 are shown at the bottom. The shaded region represents a proposed E6-AP binding domain
[25,26]. The amino acid sequences of the E6 ORFs were aligned using Clustal X (version 1.81) [36]. The amino acid at position 31 (arrow, bold) was
associated with p53 degradation (p,0.01). ‘‘_’’ indicate gaps, whereas ‘‘.’’ indicates identical residues with the HPV16 E6 amino acid sequence shown
in the top row.
doi:10.1371/journal.pone.0012816.g003
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evolution of the p53 degrading potential should allow researchers
to further tease apart the evolutionary importance of position 31
for p53 degradation. Finally, whether E6 induced p53 degradation
is a critical hallmark of HPV induced cancer or a manifestation of
evolution remains to be confirmed. These data further support
Theodosius Dobzhansky comment that ‘‘Nothing in biology makes
sense except in the light of evolution.’’
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